How to prevent glucocorticoid-induced osteoporosis

Cleveland Clinic Journal of Medicine

Volumn 77, Issue 11, 2010, Pages 762-

  Bachmeyer, Claude ^a   Gauthier, Marion ^a  

^a HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BONE DENSITY CONSERVATION AGENT; DRUG DERIVATIVE; ETIDRONIC ACID; GLUCOCORTICOID; ORGANOMETALLIC COMPOUND; RISEDRONIC ACID; STRONTIUM RANELATE; THIOPHENE DERIVATIVE;

CHEMICALLY INDUCED DISORDER; HUMAN; LETTER; OSTEOPOROSIS;

BONE DENSITY CONSERVATION AGENTS; ETIDRONIC ACID; GLUCOCORTICOIDS; HUMANS; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS; THIOPHENES;

EID: 78149485547     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.77c.10002     Document Type: Letter

References (5)

1. Dore RK. How to prevent glucocorticoid-induced osteoporosis. Cleve Clin J Med 2010; 77:529-536.
2. Ringe JD. Strontium ranelate: an effective solution for diverse fracture risks. Osteoporos Int 2010; 21 (suppl 2):S431-436.
3. Hamdy NA. Strontium ranelate improves bone microarchitecture in osteoporosis. Rheumatology (Oxford) 2009; 48:iv9-13.
4. Ringe J, Dorst A, Farahmand P. Treatment of glucocorticoid-induced osteoporosis with strontium ranelate: a 2-year observational, controlled study versus risedronate (abstract). Osteoporos Int 2009; 20(suppl 1):S72.
5. Sun P, Cai DH, Li QN, et al. Effects of alendronate and strontium ranelate on cancellous and cortical bone mass in glucocorticoid-treated adult rats. Calcif Tissue Int 2010; 86:495-501.